The North American Industry Classification System Code for this acquisition is 541711 and the size standard is 500 employees.
The National Eye Institute requires the service from the contractor for the discovery of epitopes restricted to specific molecules of human HLA class II genes and to check HLA: peptide stability. The information will be used in designing diagnostic markers for uveitis in patients. ProImmunce is the only vendor that offers this service for specific HLA class II molecules because of its association with Uveitis disease. This information is critical for the progress of our "Bench to Bedside" project. Although similar metholody is performed in other laboratories in various academic institutions, it is not provided as a service and is not available for the specific HLA class II genes that are associated with uveitis disease. ProImmune's service has been widely accepted as a high quality service and is successfully used for epitope discovery in several human diseases. The information generated by their services is instrumental in developing vaccines for some viral diseases.
No solicitation package will be issued. This notice of intent is not a request for competitive quotations; however, the Government will consider responses submitted to [email protected] on or before 10:00 AM EST, Tueday, September 6, 20111. All information furnished must be in writing and must contain sufficient detail. A determination by the Government not to compete the proposed acquisition based upon responses to this notice is solely within the discretion of the Government. Information received will normally be considered solely for the purpose of determining whether to conduct a competitive procurement. Please reference the announcement number NOI-2235959 on all correspondence submitted by email.